Experimental HIV immune therapy takes first step in healthy volunteers
NCT ID NCT07629310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single injection of JL18008, a lab-made protein designed to boost immune cells, in 40 healthy adults. The main goal was to check safety and how the body handles the drug. Researchers also measured changes in immune cell counts over 56 days. This is a first step toward possibly using JL18008 to help people with HIV who have low CD4+ T cells despite treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JL18008 (a lab-made protein that may boost immune cells)
What this could lead to
If safe, JL18008 could be tested in people with HIV to help raise their low CD4+ T cell counts, potentially improving immune function.
What could go wrong
This is a very early Phase 1 trial in only 40 healthy people. It only tests safety and dosing, not whether it works for HIV. Side effects or lack of effect in future studies are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China